Cerevel Therapeutics Holdings Inc (OQ:CERE)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 222 Jacobs Street, Suite 200
CAMBRIDGE MA 02141
Tel: N/A
Website: https://www.cerevel.com
IR: See website
<
Key People
N. Anthony Coles
Chairperson of the Board of Directors
Ronald C. Renaud
President, Chief Executive Officer, Member of the Board
Susan Altschuller
Chief Financial Officer
Kenneth Amadeo Dipietro
Chief Human Resources Officer
Mark Bodenrader
Senior Vice President - Finance, Chief Accounting Officer
John Renger
Chief Scientific Officer
Raymond Sanchez
Chief Medical Officer
Kathleen Tregoning
Chief Corporate Affairs Officer
Scott Akamine
Chief Legal Officer, Corporate Secretary
Business Overview
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder and Parkinson's disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson's disease.
Financial Overview
For the fiscal year ended 31 December 2023, Cerevel Therapeutics Holdings Inc revenues was not reported. Net loss increased 23% to $432.8M. Higher net loss reflects Research and develop increase of 14% to $229.8M (expense), Stock-based Compensation in SGA increase from $20.6M to $41.5M (expense), FV Adjustments of Financial Investment decrease from $3.4M (income) to $9.2M (expense).
Employees: 334 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $7,042M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$441.64M as of Dec 31, 2023
Net annual income (TTM): -$432.84M as of Dec 31, 2023
Free cash flow (TTM): -$346.11M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 181,576,482 as of Feb 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.